Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer-Reference-Cited by-同舟云学术

Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer

Published:2021-02 Issue: Volume:144 Page:291-301
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Kasper Stefan,Foch Caroline^ORCID,Messinger Diethelm,Esser Regina^ORCID,Lamy Francois-Xavier,Rothe Vivien^ORCID,Chen Wenfeng,Cheng Ann-Lii,Rouyer Magali,Brodowicz Thomas,Zielinski Christoph

Funder

Merck KGaA

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Holland-frei cancer medicine;Rodriguez-Bigas,2003

2. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 3;National Comprehensive Cancer Network,2020

3. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer, Version 4.;National Comprehensive Cancer Network,2020

4. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

5. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS;Yoshino;Ann Oncol,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer;Clinical Pharmacology & Therapeutics;2024-08-12

2. Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer;Nature Communications;2024-02-01

3. Cetuximab every 2 weeks versus standard weekly dosing administration schedule;Future Oncology;2023-10-18

4. Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer;Journal of Comparative Effectiveness Research;2023-02

5. Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location;European Journal of Cancer;2023-02